elbasvir
Sign in to saveElbasvir is a drug approved by the FDA in January 2016 for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, used in combination with the NS3/4A protease inhibitor grazoprevir under the trade name Zepatier, either with or without ribavirin.
Chemical data
- Formula
- C49H55N9O7
- Molecular weight
- 882 g/mol
- IUPAC name
- methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- +881.422445
Show 1 more fact
- P366
- medication
via Wikidata · CC0
Article
6 sectionsContents
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- References
{{Drugbox | IUPAC_name = Dimethyl N,N’-([(6S)-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-1-oxo-3-methylbutane-1,2-diyl]})biscarbamate | image = File:Elbasvir.svg | image_class = skin-invert-image | width = 350
| tradename = Zepatier (combination with grazoprevir) | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | licence_EU = yes | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Rx-only | routes_of_administration = Oral